Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) FCF Margin (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed FCF Margin for 15 consecutive years, with 12.99% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1636.0% year-over-year to 12.99%, compared with a TTM value of 2.46% through Oct 2025, up 518.0%, and an annual FY2025 reading of 2.46%, up 518.0% over the prior year.
  • FCF Margin was 12.99% for Q4 2025 at Pharma-Bio Serv, up from 11.94% in the prior quarter.
  • Across five years, FCF Margin topped out at 30.47% in Q1 2024 and bottomed at 29.47% in Q2 2024.
  • Average FCF Margin over 5 years is 1.87%, with a median of 6.98% recorded in 2022.
  • The sharpest move saw FCF Margin tumbled -4870bps in 2024, then surged 3974bps in 2025.
  • Year by year, FCF Margin stood at 17.27% in 2021, then plummeted by -69bps to 5.35% in 2022, then skyrocketed by 61bps to 8.62% in 2023, then tumbled by -139bps to 3.37% in 2024, then soared by 486bps to 12.99% in 2025.
  • Business Quant data shows FCF Margin for PBSV at 12.99% in Q4 2025, 11.94% in Q3 2025, and 12.65% in Q2 2025.